Advances in pharmacotherapy for wet age-related macular degeneration

Santarelli, Martina; Diplotti, Laura; Samassa, Francesco; Veritti, Daniele; Kuppermann, Baruch D.; Lanzetta, Paolo

doi:10.1517/14656566.2015.1067679

Cited by 28 publications

(17 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical manifestations of neovascular AMD include accumulation of retinal, subretinal and sub-RPE fluid. If left untreated, neovascular AMD will typically result in severe vision loss [88,89]. …”

Section: Age-related Macular Degenerationmentioning

confidence: 99%

A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders

Cehofski

Honoré

Vorum

2017

IJMS

View full text Add to dashboard Cite

Retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR) and age-related macular degeneration (AMD) are frequent ocular diseases with potentially sight-threatening outcomes. In the present review we discuss major findings of proteomic studies of RAO, RVO, DR and AMD, including an overview of ocular proteome changes associated with anti-vascular endothelial growth factor (VEGF) treatments. Despite the severe outcomes of RAO, the proteome of the disease remains largely unstudied. There is also limited knowledge about the proteome of RVO, but proteomic studies suggest that RVO is associated with remodeling of the extracellular matrix and adhesion processes. Proteomic studies of DR have resulted in the identification of potential therapeutic targets such as carbonic anhydrase-I. Proliferative diabetic retinopathy is the most intensively studied stage of DR. Proteomic studies have established VEGF, pigment epithelium-derived factor (PEDF) and complement components as key factors associated with AMD. The aim of this review is to highlight the major milestones in proteomics in RAO, RVO, DR and AMD. Through large-scale protein analyses, proteomics is bringing new important insights into these complex pathological conditions.

show abstract

Section: Age-related Macular Degenerationmentioning

confidence: 99%

A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders

Cehofski

Honoré

Vorum

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…The efficacy of anti-VEGF therapy, already widely demonstrated in in-vitro and in-vivo studies, showed fewer efficacies in real life studies than in clinical trials [19]. In recent years, many efforts were computed to find new drugs that can overcome the effectiveness of those available in the AMD therapy [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…Most studies showed their effectiveness in improving vision function and reducing macular edema. Nevertheless, intravitreal injection of corticosteroids carries significant complication risk such as cataract progression, ocular hypertension and endophthalmitis [18][19][20]. Thus, retro bulbar injections of corticosteroids are a valid alternative to intravitreal injection: it has been demonstrated to provide the same effectiveness in reducing macular edema but with a lower rate of intraocular complications [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Combined Intravitreal Bevacizumab and Retrobulbar Corticosteroids for Neovascular Age-Related Macular Degeneration

Nuzzi¹,

Dallorto²

2017

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Introduction: Inflammation plays an important role in age-related macular degeneration (AMD) pathogenesis and progression. Thus, corticosteroids have been used for macular edema associated with exudative AMD. The purpose of this study was to evaluate the efficacy and safety of combined therapy of Intravitreal Bevacizumab (IVB) with Retrobulbar (RB) injection of triamcinolone or dexamethasone (RBTA or RBDEX) in eyes with Choroidal Neovascularization (CNV) in AMD. Secondary, we compared the results with the efficacy of single intravitreal injection of bevacizumab, ranibizumab and aflibercept.

show abstract

“…In the last 10 years, several pharmacological therapies targeting VEGF have been approved for the treatment of CNV secondary to AMD. Currently, two commonly used anti-VEGF drugs (ranibizumab and aflibercept) have been approved for the intravitreal treatment of neovascular AMD by the US FDA and the European Medicines Agency, while bevacizumab, an additional anti-VEGF drug developed for systemic use, is commonly used intravitreally in an off-label fashion in many countries [11]. Bevacizumab, the first anti-VEGF agent used to treat CNV [12], is a humanized full-length monoclonal antibody that has been shown to be effective in preventing visual loss and capable of significantly improving visual acuity in AMD patients with subfoveal CNV [13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF

Vilà¹,

Coblentz²,

Neto³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To determine whether pretreatment of retinal pigmented epithelial (RPE) cells with lutein can affect the response of cells to bevacizumab therapy. Methods: One human RPE cell line (ARPE-19) was used for all experiments. The cells were treated with lutein in different concentrations (0.01, 0.1, 1, 10, or 100 μg/ml). After 24 h, all plates were treated with bevacizumab (0.25 mg/ml). Media were harvested 24 h later for sandwich ELISA-based angiogenesis arrays. A Quantibody Human Angiogenesis Array was used in order to quantify the secretion of the following 10 proangiogenic cytokines: angiogenin, ANG2, EGF, bFGF, HB-EGF, PDGF-BB, leptin, PIGF, HGF and VEGF. Results: Treatment with bevacizumab alone led to a significant decrease in VEGF, as well as a significant increase in angiogenin and bFGF. Pretreatment with 0.1 and 1.0 μg/ml of lutein led to significant decreases in both bFGF and angiogenin following treatment with bevacizumab compared to bevacizumab treatment alone. Lutein alone did not modify the secretion of proangiogenic cytokines. Conclusions: Pretreatment of human RPE cells in culture with specific doses of lutein prior to bevacizumab treatment mitigated the increase in bFGF and angiogenin caused by bevacizumab monotherapy.

show abstract

Advances in pharmacotherapy for wet age-related macular degeneration

Cited by 28 publications

References 70 publications

A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders

A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders

Efficacy and Safety of Combined Intravitreal Bevacizumab and Retrobulbar Corticosteroids for Neovascular Age-Related Macular Degeneration

Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF

Contact Info

Product

Resources

About